Brain Tumor Res Treat.  2017 Oct;5(2):64-69. 10.14791/btrt.2017.5.2.64.

Genomic and Molecular Characterization of Brain Tumors in Asian and Non-Asian Patients of Los Angeles: A Single Institution Analysis

• Duong C
• Nguyen T
• Sheppard J
• Ong V
• Chung LK
• Nagasawa D
• Yang I

• KMID: 2396449
• DOI: http://doi.org/10.14791/btrt.2017.5.2.64

Abstract

BACKGROUND
Worldwide, approximately 2% of new cancers are of the brain. Five-year survival rates among brain cancer patients have been reported as a little over a third. Differences in clinical outcomes between brain tumor patients of different races remain poorly understood.
METHODS
A retrospective chart review was performed on brain tumor resection patients≥18 years old. Demographics, treatment variables, and survival outcomes were collected. Primary outcomes were length of stay, recurrence rate, progression-free survival (PFS), and overall survival (OS).
RESULTS
A total of 452 patients were included in analysis. Females and males had nearly a 1:1 ratio (n=242 and n=220, respectively). Mean age was 54.8 years (SD: 14.5 range: 18-90). Females composed 69% (n=48) of Asian patients; males constituted 31% (n=22). Mean age of the Asian patients was 55.9 years (SD: 14.6 range: 26-89). Asian-only cohort tumor pathologies included glioblastoma (GBM) (n=14), high-grade glioma (n=7), low-grade glioma (n=4), meningioma (n=38), and metastases (n=7). Of the 185 meningioma patients, non-Asian patients comprised 79% of the group (n=146). Of the 65 GBM patients in total, non-Asian patients made up 89% of the GBM cohort (n=58). There were no statistically significant differences between these groups of both cohorts in recurrence (p=0.1580 and p=0.6294, respectively), PFS (p=0.9662 and p=0.4048, respectively), or OS (p=0.3711 and p=0.8183, respectively).
CONCLUSION
Studies evaluating the survival between patients of different racial backgrounds against several tumor varieties are rare. Patients of certain racial backgrounds may need additional consideration when being attended to despite the same mutational composition as their counterparts. Repeated studies using national databases may yield more conclusive results.

Keyword

Biomarkers; Race; Glioblastoma; Meningioma; Brain neoplasms

MeSH Terms

Asian Continental Ancestry Group*
Biomarkers
Brain Neoplasms*
Brain*
Cohort Studies
Continental Population Groups
Demography
Disease-Free Survival
Female
Glioblastoma
Glioma
Humans
Length of Stay
Male
Meningioma
Neoplasm Metastasis
Pathology
Recurrence
Retrospective Studies
Survival Rate
Biomarkers

Reference

1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136:E359–E386.

2. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review (CSR) 1975-2014. Bethesda, MD: National Cancer Institute;Accessed July 28, 2017. https://seer.cancer.gov/csr/1975_2014.

3. Chen JG, Zhu J, Zhang YH, et al. Cancer survival in Qidong between 1972 and 2011: a population-based analysis. Mol Clin Oncol. 2017; 6:944–954.

4. Brown M, Schrot R, Bauer K, Dodge J. Incidence of first primary central nervous system tumors in California, 2001-2005: children, adolescents and teens. J Neurooncol. 2009; 94:263–273.

5. Das A, Tang WY, Smith DR. Meningiomas in Singapore: demographic and biological characteristics. J Neurooncol. 2000; 47:153–160.

6. Dubrow R, Darefsky AS. Demographic variation in incidence of adult glioma by subtype, United States, 1992-2007. BMC Cancer. 2011; 11:325.

7. Gittleman H, Ostrom QT, Farah PD, et al. Descriptive epidemiology of pituitary tumors in the United States, 2004-2009. J Neurosurg. 2014; 121:527–535.

8. Maile EJ, Barnes I, Finlayson AE, Sayeed S, Ali R. Nervous system and intracranial tumour incidence by ethnicity in England, 2001-2007: a descriptive epidemiological study. PLoS One. 2016; 11:e0154347.

9. Kohler BA, Ward E, McCarthy BJ, et al. Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst. 2011; 103:714–736.

10. Linabery AM, Ross JA. Trends in childhood cancer incidence in the U.S. (1992-2004). Cancer. 2008; 112:416–432.

11. Howard SC, Metzger ML, Wilimas JA, et al. Childhood cancer epidemiology in low-income countries. Cancer. 2008; 112:461–472.

12. Heshmat MY, Kovi J, Simpson C, Kennedy J, Fan KJ. Neoplasms of the central nervous system. Incidence and population selectivity in the Washington DC, metropolitan area. Cancer. 1976; 38:2135–2142.

13. Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol. 2005; 109:93–108.

14. Davis FG, McCarthy B, Jukich P. The descriptive epidemiology of brain tumors. Neuroimaging Clin N Am. 1999; 9:581–594.

15. Fan KJ, Pezeshkpour GH. Ethnic distribution of primary central nervous system tumors in Washington, DC, 1971 to 1985. J Natl Med Assoc. 1992; 84:858–863.

16. Jukich PJ, McCarthy BJ, Surawicz TS, Freels S, Davis FG. Trends in incidence of primary brain tumors in the United States, 1985-1994. Neuro Oncol. 2001; 3:141–151.

17. Kuratsu J, Takeshima H, Ushio Y. Trends in the incidence of primary intracranial tumors in Kumamoto, Japan. Int J Clin Oncol. 2001; 6:183–191.

18. McLendon RE, Robinson JS Jr, Chambers DB, Grufferman S, Burger PC. The glioblastoma multiforme in Georgia, 1977-1981. Cancer. 1985; 56:894–897.

19. Stiller CA, Nectoux J. International incidence of childhood brain and spinal tumours. Int J Epidemiol. 1994; 23:458–464.

20. Deorah S, Lynch CF, Sibenaller ZA, Ryken TC. Trends in brain cancer incidence and survival in the United States: Surveillance, Epidemiology, and End Results Program, 1973 to 2001. Neurosurg Focus. 2006; 20:E1.

21. Chakrabarti I, Cockburn M, Cozen W, Wang YP, Preston-Martin S. A population-based description of glioblastoma multiforme in Los Angeles County, 1974-1999. Cancer. 2005; 104:2798–2806.

22. Preston-Martin S. Descriptive epidemiology of primary tumors of the brain, cranial nerves and cranial meninges in Los Angeles County. Neuroepidemiology. 1989; 8:283–295.

23. Barnholtz-Sloan JS, Sloan AE, Schwartz AG. Racial differences in survival after diagnosis with primary malignant brain tumor. Cancer. 2003; 98:603–609.

24. Sadetzki S, Modan B, Chetrit A, Freedman L. An iatrogenic epidemic of benign meningioma. Am J Epidemiol. 2000; 151:266–272.

25. Thumma SR, Fairbanks RK, Lamoreaux WT, et al. Effect of pretreatment clinical factors on overall survival in glioblastoma multiforme: a Surveillance Epidemiology and End Results (SEER) population analysis. World J Surg Oncol. 2012; 10:75.

26. Barnholtz-Sloan JS, Maldonado JL, Williams VL, et al. Racial/ethnic differences in survival among elderly patients with a primary glioblastoma. J Neurooncol. 2007; 85:171–180.

27. Robertson JT, Gunter BC, Somes GW. Racial differences in the incidence of gliomas: a retrospective study from Memphis, Tennessee. Br J Neurosurg. 2002; 16:562–566.

28. Wu CC, Wang TJ, Jani A, et al. A modern radiotherapy series of survival in Hispanic patients with glioblastoma. World Neurosurg. 2016; 88:260–269.

29. Sze M, Butow P, Bell M, et al. Migrant health in cancer: outcome disparities and the determinant role of migrant-specific variables. Oncologist. 2015; 20:523–531.

30. Grenade C, Phelps MA, Villalona-Calero MA. Race and ethnicity in cancer therapy: what have we learned? Clin Pharmacol Ther. 2014; 95:403–412.

31. Allard JE, Maxwell GL. Race disparities between black and white women in the incidence, treatment, and prognosis of endometrial cancer. Cancer Control. 2009; 16:53–56.

32. Aizer AA, Ancukiewicz M, Nguyen PL, Shih HA, Loeffler JS, Oh KS. Underutilization of radiation therapy in patients with glioblastoma: predictive factors and outcomes. Cancer. 2014; 120:238–243.

33. Dai Y, Ning X, Han G, Li W. Assessment of the association between isocitrate dehydrogenase 1 mutation and mortality risk of glioblastoma patients. Mol Neurobiol. 2016; 53:1501–1508.

34. Jung KW, Yoo H, Kong HJ, Won YJ, Park S, Lee SH. Population-based survival data for brain tumors in Korea. J Neurooncol. 2012; 109:301–307.

35. Mukasa A, Takayanagi S, Saito K, et al. Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients. Cancer Sci. 2012; 103:587–592.

36. Hoeffel EM, Rastogi S, Kim MO, Shahid H. The Asian population: 2010. US census bureau;2010. Accessed March 23, 2016. https://www.census.gov/prod/cen2010/briefs/c2010br-11.pdf.

37. Humes KR, Jones NA, Ramirez RR. Overview of Race and Hispanic Origin: 2010. US census bureau;2010. Accessed March 23, 2016. https://www.census.gov/prod/cen2010/briefs/c2010br-02.pdf.

38. Nomura K. Epidemiology of germ cell tumors in Asia of pineal region tumor. J Neurooncol. 2001; 54:211–217.

39. Araki C, Matsumoto S. Statistical reevaluation of pinealoma and related tumors in Japan. J Neurosurg. 1969; 30:146–149.

40. Oi S, Matsuzawa K, Choi JU, Kim DS, Kang JK, Cho BK. Identical characteristics of the patient populations with pineal region tumors in Japan and in Korea and therapeutic modalities. Childs Nerv Syst. 1998; 14:36–40.

41. Surawicz TS, Davis F, Freels S, Laws ER Jr, Menck HR. Brain tumor survival: results from the National Cancer Data Base. J Neurooncol. 1998; 40:151–160.

42. Ostrom QT, Gittleman H, Xu J, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2009-2013. Neuro Oncol. 2016; 18:suppl_5. v1–v75.

43. Sanson M, Marie Y, Paris S, et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol. 20091; 27:4150–4154.

44. Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol. 2009; 27:5743–5750.

45. Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol. 2010; 120:707–718.

46. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008; 321:1807–1812.

47. Carrillo JA, Lai A, Nghiemphu PL, et al. Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma. Am J Neuroradiol. 2012; 33:1349–1355.

48. Juratli TA, Kirsch M, Geiger K, et al. The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas. J Neurooncol. 2012; 110:325–333.

49. Phillips JJ, Aranda D, Ellison DW, et al. PDGFRA amplification is common in pediatric and adult high-grade astrocytomas and identifies a poor prognostic group in IDH1 mutant glioblastoma. Brain Pathol. 2013; 23:565–573.

50. Shin JH, Lee YS, Hong YK, Kang CS. Correlation between the prognostic value and the expression of the stem cell marker CD133 and isocitrate dehydrogenase1 in glioblastomas. J Neurooncol. 2013; 115:333–341.

51. Labussière M, Boisselier B, Mokhtari K, et al. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes. Neurology. 2014; 83:1200–1206.

52. Molenaar RJ, Verbaan D, Lamba S, et al. The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone. Neuro Oncol. 2014; 16:1263–1273.

53. Bleeker FE, Atai NA, Lamba S, et al. The prognostic IDH1( R132 ) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma. Acta Neuropathol. 2010; 119:487–494.

54. Killela PJ, Pirozzi CJ, Healy P, et al. Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas. Oncotarget. 2014; 5:1515–1525.

55. Castells X, Acebes JJ, Majós C, et al. Development of robust discriminant equations for assessing subtypes of glioblastoma biopsies. Br J Cancer. 2012; 106:1816–1825.

56. Stancheva G, Goranova T, Laleva M, et al. IDH1/IDH2 but not TP53 mutations predict prognosis in Bulgarian glioblastoma patients. Biomed Res Int. 2014; 2014:654727.

57. Takahashi Y, Nakamura H, Makino K, et al. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients. World J Surg Oncol. 2013; 11:284.

58. Wang XW, Boisselier B, Rossetto M, et al. Prognostic impact of the isocitrate dehydrogenase 1 single-nucleotide polymorphism rs11554137 in malignant gliomas. Cancer. 2013; 119:806–813.

59. Yan W, Zhang W, You G, et al. Correlation of IDH1 mutation with clinicopathologic factors and prognosis in primary glioblastoma: a report of 118 patients from China. PLoS One. 2012; 7:e30339.

60. Zhang W, Zhang J, Yan W, et al. Whole-genome microRNA expression profiling identifies a 5-microRNA signature as a prognostic biomarker in Chinese patients with primary glioblastoma multiforme. Cancer. 2013; 119:814–824.

61. Das A, Tan WL, Teo J, Smith DR. Glioblastoma multiforme in an Asian population: evidence for a distinct genetic pathway. J Neurooncol. 2002; 60:117–125.

62. Watanabe K, Tachibana O, Sata K, Yonekawa Y, Kleihues P, Ohgaki H. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol. 1996; 6:217–223. discussion 223-4.

63. Ng HK, Lo SY, Huang DP, Poon WS. Paraffin section p53 protein immunohistochemistry in neuroectodermal tumors. Pathology. 1994; 26:1–5.

64. Wang Y, Pan L, Sheng XF, Chen S, Dai JZ. Nimotuzumab, a humanized monoclonal antibody specific for the EGFR, in combination with temozolomide and radiation therapy for newly diagnosed glioblastoma multiforme: first results in Chinese patients. Asia Pac J Clin Oncol. 2016; 12:e23–e29.

65. Yang H, Wei D, Yang K, Tang W, Luo Y, Zhang J. The prognosis of MGMT promoter methylation in glioblastoma patients of different race: a meta-analysis. Neurochem Res. 2014; 39:2277–2287.

66. Lehrer S, Green S, Ramanathan L, Rosenzweig K, Labombardi V. No consistent relationship of glioblastoma incidence and cytomegalovirus seropositivity in whites, blacks, and Hispanics. Anticancer Res. 2012; 32:1113–1115.

67. Krishnamachari B, Il'yasova D, Scheurer ME, et al. A pooled multisite analysis of the effects of atopic medical conditions in glioma risk in different ethnic groups. Ann Epidemiol. 2015; 25:270–274.

68. Tang J, Shao W, Dorak MT, et al. Positive and negative associations of human leukocyte antigen variants with the onset and prognosis of adult glioblastoma multiforme. Cancer Epidemiol Biomarkers Prev. 2005; 14:2040–2044.

69. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 1999; 59:793–797.

70. Hegi ME, Liu L, Herman JG, et al. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol. 2008; 26:4189–4199.

71. Kitange GJ, Carlson BL, Mladek AC, et al. Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model. J Neurooncol. 2009; 92:23–31.

72. Amatu A, Sartore-Bianchi A, Moutinho C, et al. Promoter CpG island hypermethylation of the DNA repair enzyme MGMT predicts clinical response to dacarbazine in a phase II study for metastatic colorectal cancer. Clin Cancer Res. 2013; 19:2265–2272.

73. Kepes J. Meningiomas. Biology, Pathology and Differential Diagnosis. New York: Masson;1982.

74. Bondy M, Ligon BL. Epidemiology and etiology of intracranial meningiomas: a review. J Neurooncol. 1996; 29:197–205.

75. Rachlin JR, Rosenblum ML. Etiology and biology of meningiomas. In : Al-Mefty O, editor. Meningiomas. NY: Raven Press;1991. p. 27–35.

76. Sadetzki S, Zach L, Chetrit A, et al. Epidemiology of gliomas in Israel: a nationwide study. Neuroepidemiology. 2008; 31:264–269.

77. Pashaki AS, Hamed EA, Mohamadian K, Abassi M, Safaei AM, Torkaman T. Efficacy of high dose radiotherapy in post-operative treatment of glioblastoma multiform--a single institution report. Asian Pac J Cancer Prev. 2014; 15:2793–2796.

78. Gurney JG, Kadan-Lottick N. Brain and other central nervous system tumors: rates, trends, and epidemiology. Curr Opin Oncol. 2001; 13:160–166.

79. Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol. 2005; 64:479–489.

80. Elia-Pasquet S, Provost D, Jaffré A, et al. Incidence of central nervous system tumors in Gironde, France. Neuroepidemiology. 2004; 23:110–117.

81. Fleury A, Menegoz F, Grosclaude P, et al. Descriptive epidemiology of cerebral gliomas in France. Cancer. 1997; 79:1195–1202.

82. Iwamoto FM, Reiner AS, Nayak L, Panageas KS, Elkin EB, Abrey LE. Prognosis and patterns of care in elderly patients with glioma. Cancer. 2009; 115:5534–5540.

83. Formenti SC, Meyerowitz BE, Ell K, et al. Inadequate adherence to radiotherapy in Latina immigrants with carcinoma of the cervix. Potential impact on disease free survival. Cancer. 1995; 75:1135–1140.